Abstract | OBJECTIVE: METHODS: A prospective, open, randomized, controlled, single-center clinical observation was conducted. In total, 107 patients were randomly assigned to receive calcium polystyrene sulfonate at 15 (group A) or 30 mg/day (group B) for 1 week. Patients were assessed on days 0, 3, and 7. RESULTS: After 3 days of treatment, the serum potassium levels in groups A and B had decreased by 0.68 ± 0.46 and 0.75 ± 0.43 mmol/L, respectively. After 7 days, the serum potassium levels in groups A and B had decreased by 0.64 ± 0.37 and 0.94 ± 0.49 mmol/L, respectively. Conversely, serum sodium, phosphorus, and calcium levels did not significantly change during the treatment period. Constipation was the most common adverse drug reaction, and no treatment-related serious adverse events were observed. CONCLUSION:
|
Authors | Xia Wang, Dacheng Chen, Xia Song, Jinquan Wang, Haitao Zhang |
Journal | The Journal of international medical research
(J Int Med Res)
Vol. 51
Issue 4
Pg. 3000605231167516
(Apr 2023)
ISSN: 1473-2300 [Electronic] England |
PMID | 37063062
(Publication Type: Randomized Controlled Trial, Journal Article)
|
Chemical References |
- polystyrene sulfonic acid
- Calcium
- Potassium
- Sodium
- Phosphorus
|
Topics |
- Humans
- Hyperkalemia
(drug therapy)
- Calcium
- Prospective Studies
- Potassium
- Kidney Failure, Chronic
(complications, drug therapy)
- Sodium
- Phosphorus
|